The combination of tezacaftor and ivacaftor in the treatment of patients with cystic fibrosis: clinical evidence and future prospects in cystic fibrosis therapy

Years of tremendous study have dawned a new era for the treatment of cystic fibrosis (CF). For years CF care was rooted in the management of organ dysfunction resulting from the mal-effects of absent anion transport through the CF transmembrane regulator (CFTR) protein. CFTR, an adenosine triphospha...

Descripción completa

Detalles Bibliográficos
Autores principales: Lommatzsch, Sherstin T., Taylor-Cousar, Jennifer L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487765/
https://www.ncbi.nlm.nih.gov/pubmed/31027466
http://dx.doi.org/10.1177/1753466619844424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6487765/
https://www.ncbi.nlm.nih.gov/pubmed/31027466
http://dx.doi.org/10.1177/1753466619844424

Ejemplares similares